Invention Grant
- Patent Title: Heterocyclic compound
-
Application No.: US15210965Application Date: 2016-07-15
-
Publication No.: US10308643B2Publication Date: 2019-06-04
- Inventor: Akira Kaieda , Masashi Toyofuku , Masaki Daini , Hiroshi Nara , Masato Yoshikawa , Naoki Ishii , Kousuke Hidaka
- Applicant: Takeda Pharmaceutical Company Limited
- Applicant Address: JP Osaka
- Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee Address: JP Osaka
- Agency: Hamre, Schumann, Mueller & Larson, P.C.
- Priority: JP2015-143354 20150717; JP2016-029020 20160218
- Main IPC: C07D413/14
- IPC: C07D413/14 ; C07D413/04 ; C07D471/04 ; C07D491/08 ; C07D491/107 ; C07D417/14 ; C07D498/08

Abstract:
The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a pharmaceutical composition comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
Public/Granted literature
- US20170015655A1 HETEROCYCLIC COMPOUND Public/Granted day:2017-01-19
Information query